Status:
COMPLETED
An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients
Lead Sponsor:
AstraZeneca
Conditions:
Barrett's Esophagus
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to compare the treatment of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients
Eligibility Criteria
Inclusion
- Documented history (within 2 yrs of histologically proven BE;
- Aged 18-70 (inclusive);
- Willing and able to comply with all study procedures
Exclusion
- Signs of clinically significant GI bleeding within 3 days prior to randomization;
- History of gastric or esophageal surgery;
- Clinically significant illness within 2 weeks prior to first dose of study drug or during study
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00352261
Start Date
January 1 2006
End Date
April 1 2007
Last Update
March 26 2009
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Phoenix, Arizona, United States
2
Research Site
Tucson, Arizona, United States
3
Research Site
North Chicago, Illinois, United States
4
Research Site
Rochester, Minnesota, United States